THOMAS BERBOS is effectively a Medicare-focused ophthalmology practice with $2.7M in lifetime Medicare revenue and no Medicaid billing on file; this means payer mix is single-payer dominated and any Medicaid network strategies are not evidenced in the claims record. The provider’s NPI has been enumerated since 2005-12-22 (~21 years), indicating long tenure and an established practice presence in HELENA, MT. The Medicare revenue is highly concentrated: the top three Medicare codes by revenue account for 83.7% of total Medicare revenue, signaling reliance on a small set of high-value services rather than a broad, diversified procedure mix. Aflibercept injection J0178 is the dominant revenue driver (J0178: $1.8M, 67.1% of Medicare revenue) and constitutes the majority of billed value, which suggests the practice’s service line is heavily oriented toward intravitreal pharmacologic therapy for retinal disease. Two other high-revenue items are J2777 (faricimab) and 67028 (isolated intravitreal injection), which together with J0178 make up the precomputed top-three share; this combination reinforces that in-office retinal injections and associated retinal procedure work are the core business operations. The provider shows notably high volume on several diagnostic and imaging E/M codes: 92014 and 92134 both appear at or above the 97th–98th percentile nationally (92014 at the 98th percentile and 92134 flagged as an extreme outlier, 97th percentile), indicating above-typical throughput of comprehensive established exams and OCT retinal imaging relative to peers and consistent follow-up care for retinal disease. For surgical cataract codes the provider reports modest volumes (e.g., 66984, 66982, 66821) with percentile ranks in the typical range; cataract surgery is present but not a primary revenue focus. Competitively, the provider is a substantial but not dominant national participant for certain retinal therapeutics (J0178 ranks #272 of 3204, 92nd percentile—typical/unremarkable volume) while displaying extreme relative intensity in retinal imaging (92134) and high examination volumes (92014), suggesting local leadership in retinal diagnostics and medical retina management rather than high-volume surgical subspecialty domination.